BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

681 related articles for article (PubMed ID: 23782950)

  • 1. Selenium supplementation for patients with Graves' hyperthyroidism (the GRASS trial): study protocol for a randomized controlled trial.
    Watt T; Cramon P; Bjorner JB; Bonnema SJ; Feldt-Rasmussen U; Gluud C; Gram J; Hansen JL; Hegedüs L; Knudsen N; Bach-Mortensen P; Nolsøe R; Nygaard B; Pociot F; Skoog M; Winkel P; Rasmussen AK
    Trials; 2013 Apr; 14():119. PubMed ID: 23782950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The chronic autoimmune thyroiditis quality of life selenium trial (CATALYST): study protocol for a randomized controlled trial.
    Winther KH; Watt T; Bjørner JB; Cramon P; Feldt-Rasmussen U; Gluud C; Gram J; Groenvold M; Hegedüs L; Knudsen N; Rasmussen ÅK; Bonnema SJ
    Trials; 2014 Apr; 15():115. PubMed ID: 24716668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Long-Term Outcome of Treatment for Graves' Hyperthyroidism.
    Sjölin G; Holmberg M; Törring O; Byström K; Khamisi S; de Laval D; Abraham-Nordling M; Calissendorff J; Lantz M; Hallengren B; Filipsson Nyström H; Wallin G
    Thyroid; 2019 Nov; 29(11):1545-1557. PubMed ID: 31482765
    [No Abstract]   [Full Text] [Related]  

  • 4. Thyroid surgery for Graves' disease and Graves' ophthalmopathy.
    Liu ZW; Masterson L; Fish B; Jani P; Chatterjee K
    Cochrane Database Syst Rev; 2015 Nov; 2015(11):CD010576. PubMed ID: 26606533
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radioiodine therapy versus antithyroid medications for Graves' disease.
    Ma C; Xie J; Wang H; Li J; Chen S
    Cochrane Database Syst Rev; 2016 Feb; 2(2):CD010094. PubMed ID: 26891370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Challenges and perspectives of selenium supplementation in Graves' disease and orbitopathy.
    Bednarczuk T; Schomburg L
    Hormones (Athens); 2020 Mar; 19(1):31-39. PubMed ID: 31721133
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained control of Graves' hyperthyroidism during long-term low-dose antithyroid drug therapy of patients with severe Graves' orbitopathy.
    Laurberg P; Berman DC; Andersen S; Bülow Pedersen I
    Thyroid; 2011 Sep; 21(9):951-6. PubMed ID: 21834677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant rituximab, a potential treatment for the young patient with Graves' hyperthyroidism (RiGD): study protocol for a single-arm, single-stage, phase II trial.
    Cole M; Hynes AM; Howel D; Hall L; Abinun M; Allahabadia A; Barrett T; Boelaert K; Drake AJ; Dimitri P; Kirk J; Zammitt N; Pearce S; Cheetham T
    BMJ Open; 2019 Jan; 9(1):e024705. PubMed ID: 30670519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impaired Quality of Life After Radioiodine Therapy Compared to Antithyroid Drugs or Surgical Treatment for Graves' Hyperthyroidism: A Long-Term Follow-Up with the Thyroid-Related Patient-Reported Outcome Questionnaire and 36-Item Short Form Health Status Survey.
    Törring O; Watt T; Sjölin G; Byström K; Abraham-Nordling M; Calissendorff J; Cramon PK; Filipsson Nyström H; Hallengren B; Holmberg M; Khamisi S; Lantz M; Wallin G
    Thyroid; 2019 Mar; 29(3):322-331. PubMed ID: 30667296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is there a methimazole dose effect on remission rate in Graves' disease? Results from a long-term prospective study. The European Multicentre Trial Group of the Treatment of Hyperthyroidism with Antithyroid Drugs.
    Benker G; Reinwein D; Kahaly G; Tegler L; Alexander WD; Fassbinder J; Hirche H
    Clin Endocrinol (Oxf); 1998 Oct; 49(4):451-7. PubMed ID: 9876342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistent Graves' hyperthyroidism despite rapid negative conversion of thyroid-stimulating hormone-binding inhibitory immunoglobulin assay results: a case report.
    Ohara N; Kaneko M; Kitazawa M; Uemura Y; Minagawa S; Miyakoshi M; Kaneko K; Kamoi K
    J Med Case Rep; 2017 Feb; 11(1):32. PubMed ID: 28162094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Vitamin D Supplementation on Graves' Disease: The DAGMAR Trial.
    Grove-Laugesen D; Ebbehoj E; Watt T; Riis AL; Østergård T; Bruun BJ; Juel Christiansen J; Hansen KW; Rejnmark L
    Thyroid; 2023 Sep; 33(9):1110-1118. PubMed ID: 37218433
    [No Abstract]   [Full Text] [Related]  

  • 13. Graves' disease in children.
    Léger J; Oliver I; Rodrigue D; Lambert AS; Coutant R
    Ann Endocrinol (Paris); 2018 Dec; 79(6):647-655. PubMed ID: 30180972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidemiology, management and outcomes of Graves' disease-real life data.
    Hussain YS; Hookham JC; Allahabadia A; Balasubramanian SP
    Endocrine; 2017 Jun; 56(3):568-578. PubMed ID: 28478488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of chronic iodine administration on thyroid status in euthyroid subjects previously treated with antithyroid drugs for Graves' hyperthyroidism.
    Roti E; Gardini E; Minelli R; Bianconi L; Salvi M; Gavaruzzi G; Braverman LE
    J Clin Endocrinol Metab; 1993 Apr; 76(4):928-32. PubMed ID: 7682562
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term remission following antithyroid drug withdrawal in patients with Graves' hyperthyroidism: parameters with prognostic value.
    García-Mayor RV; Álvarez-Vázquez P; Fluiters E; Valverde D; Andrade A
    Endocrine; 2019 Feb; 63(2):316-322. PubMed ID: 30334140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnosis and treatment of Graves disease.
    Streetman DD; Khanderia U
    Ann Pharmacother; 2003; 37(7-8):1100-9. PubMed ID: 12841824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of selenium on short-term control of hyperthyroidism due to Graves' disease treated with methimazole: results of a randomized clinical trial.
    Leo M; Bartalena L; Rotondo Dottore G; Piantanida E; Premoli P; Ionni I; Di Cera M; Masiello E; Sassi L; Tanda ML; Latrofa F; Vitti P; Marcocci C; Marinò M
    J Endocrinol Invest; 2017 Mar; 40(3):281-287. PubMed ID: 27734319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary therapy of Graves' disease and cardiovascular morbidity and mortality: a linked-record cohort study.
    Okosieme OE; Taylor PN; Evans C; Thayer D; Chai A; Khan I; Draman MS; Tennant B; Geen J; Sayers A; French R; Lazarus JH; Premawardhana LD; Dayan CM
    Lancet Diabetes Endocrinol; 2019 Apr; 7(4):278-287. PubMed ID: 30827829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quality-of-Life Impairments Persist Six Months After Treatment of Graves' Hyperthyroidism and Toxic Nodular Goiter: A Prospective Cohort Study.
    Cramon P; Winther KH; Watt T; Bonnema SJ; Bjorner JB; Ekholm O; Groenvold M; Hegedüs L; Feldt-Rasmussen U; Rasmussen ÅK
    Thyroid; 2016 Aug; 26(8):1010-8. PubMed ID: 27370744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.